中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 9
Sep.  2020
Turn off MathJax
Article Contents

Development and prognosis of acute-on-chronic liver failure in patients with acute deterioration of hepatitis B virus-related liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2020.09.010
Research funding:

 

  • Received Date: 2020-04-02
  • Published Date: 2020-09-20
  • Objective To investigate the 28-day incidence rate of acute-on-chronic liver failure( ACLF) and the 90-day prognosis of patients with acute deterioration( AD) of hepatitis B virus( HBV)-related liver cirrhosis( LC). Methods A total of 670 patients with AD of HBV-related LC who were admitted to The Fifth Medical Center of Chinese PLA General Hospital from October 2014 to October 2016 were enrolled,and according to total bilirubin( TBil) and prothrombin time activity( PTA),they were divided into group A with 134 patients( 51. 3 μmol/L < TBil < 171. 1 μmol/L and PTA < 40%),group B with 393 patients( 51. 3 μmol/L < TBil < 171. 1 μmol/L and40% ≤PTA < 60%),and group C with 143 patients( TBil > 171. 1 μmol/L and 40% < PTA < 60%). The patients were analyzed in terms of clinical features,28-day incidence rate of ACLF and its influencing factors,and 90-day survival and its influencing factors. Ananalysis of variance was used for comparison of normally distributed continuous data between multiple groups,and the least significant difference t-test was used for further comparison between two groups; the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups. The chi-square test or the Fisher's exact test was used for comparison of categorical data between multiple groups. The Kaplan-Meier method was used to calculate cumulative incidence rate,and the log-rank test was used for comparison between groups. Cox regression analysis and logistic regression analysis were used to investigate the influencing factors for the onset of ACLF and 90-day survival. Results There were significant differences between groups A,B,and C in Model for End-Stage Liver Disease score( 20. 2 ± 4. 6 vs 14. 7 ± 3. 6 vs 22. 7 ± 5. 6,F = 211. 118,P < 0. 001) and Child-Pugh score( 10. 6 ± 0. 8 vs 9. 3 ± 1. 2 vs10. 4 ± 1. 2,F = 66. 427,P < 0. 001),and group B had significantly lower scores than groups A and C( all P < 0. 05). Among the 670 patients,69( 10. 3%) developed ACLF within 28 days,with 19 patients( 14. 2%) in group A,17 patients( 4. 3%) in group B,and 33 patients( 23. 1%) in group C. Group B had a significantly lower incidence rate of ACLF than group A( χ2= 15. 937,P < 0. 001) and group C( χ2= 48. 502,P < 0. 001). In group A,aspartate aminotransferase( AST)( risk ratio [RR]= 1. 033,P = 0. 030),bacterial infections( BIs)( RR = 14. 326,P = 0. 001),blood sodium( Na)( RR = 0. 888,P = 0. 019),and alpha-fetoprotein( AFP)( RR = 1. 003,P <0. 001) were independent influencing factors for ACLF; in group B,male sex( RR = 0. 201,P = 0. 035),alanine aminotransferase( RR =0. 996,P = 0. 006),AST( RR = 1. 008,P < 0. 001),gamma-glutamyl transpeptidase( RR = 1. 004,P = 0. 018),PTA( RR = 0. 642,P < 0. 001),TBil( RR = 1. 039,P = 0. 002),BIs( RR = 49. 656,P < 0. 001),and HBV DNA( RR = 2. 206,P < 0. 001) were independent influencing factors for ACLF; in group C,acute variceal bleeding( AVB)( RR = 3. 172,P = 0. 025) and BIs( RR = 2. 946,P =0. 007) were independent influencing factors for ACLF. Of all 670 patients,79( 11. 8%) died within 90 days,with 29 patients( 21. 6%)in group A,15 patients( 3. 8%) in group B,and 35 patients( 24. 5%) in group C,and group B had a significantly lower mortality rate than group A( χ2= 41. 492,P < 0. 001) and group C( χ2= 52. 905,P < 0. 001). In each group,the patients with ACLF had a significantly higher 90-day mortality rate than those without ACLF( group A: χ2= 4. 151,P = 0. 042; group B: P = 0. 022; group C: χ2= 16. 968,P< 0. 001). In group A,creatinine( odds ratio [OR]= 1. 075,P = 0. 007) and Na( OR = 0. 450,P < 0. 001) were independent influencing factors for 90-day survival; in group B,AVB( OR = 1378. 999,P = 0. 026) and Na( OR = 0. 392,P = 0. 018) were independent influencing factors for 90-day survival; in group C,AVB( OR = 31. 699,P = 0. 038),Na( OR = 0. 841,P = 0. 023),and development of ACLF( OR = 14. 258,P = 0. 017) were independent influencing factors for 90-day survival. Conclusion Patients with AD of HBV-related LC can be divided into three clinical types,and the patients with high jaundice type( group C) or low coagulation type( group A) tend to develop ACLF and have poorer prognosis. BIs are the common influencing factor for ACLF in these three types of patients,and blood Na level is the common influencing factor for 90-day prognosis.

     

  • loading
  • [1] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association; Severe Liver Disease and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol,2019,35(1):38-44.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版)[J].临床肝胆病杂志,2019,35(1):38-44.
    [2] LI C,LYU S,ZHU B,et al. Risk factors for short-term outcome of patients with HBV-related acute-on-chronic liver failure[J]. Chin J Hepatol,2016,24(3):207-213.(in Chinese)李晨,吕飒,朱冰,等.乙型肝炎病毒相关慢加急性肝衰竭患者近期预后危险因素的研究[J].中华肝脏病杂志,2016,24(3):207-213.
    [3] LI C,ZHU B,LV S,et al. Prediction model of the progression of patients with acute deterioration of hepatitis B virus-related chronic liver disease to acute-on-chronic liver failure[J].Medicine(Baltimore),2018,97(34):e11915.
    [4] LI C,ZHU B,LYU S,et al. Discussion and evaluation of diagnostic criteria for hepatitis B virus-related acute-on-chronic pre-liver failure[J]. Chin J Hepatol,2018,26(2):130-135.(in Chinese)李晨,朱冰,吕飒,等.乙型肝炎病毒相关慢加急性肝衰竭前期患者诊断标准的探讨[J].中华肝脏病杂志,2018,26(2):130-135.
    [5] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408-2425.
    [6] KAMATH PS,WIESNER RH,MALINCHOC M,et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology,2001,33(2):464-470.
    [7] PUGH RN,MURRAY-LYON IM,DAWSON JL,et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg,1973,60(8):646-649.
    [8] ZHENG Y,LI YG. Research advances in predisposing factors for acute-on-chronic hepatitis B liver failure[J]. J Clin Hepatol,2017,33(9):1802-1805.(in Chinese)郑颖,李用国.乙型肝炎相关慢加急性肝衰竭诱因的研究进展[J].临床肝胆病杂志,2017,33(9):1802-1805.
    [9] CHEN F,SHI Y,LIU X,et al. Corticosteroid improves liver function but does not curb the clinical progression of hepatitis B virus-related acute-on-chronic pre-liver failure[J]. Expert Rev Gastroenterol Hepatol,2019,13(11):1129-1135.
    [10] JALAN R,YURDAYDIN C,BAJAJ JS,et al. Toward an improved definition of acute-on-chronic liver failure[J]. Gastroenterology,2014,147(1):4-10.
    [11] XU TJ,LYU S,YOU SL,et al. Clinical features and typing of hepatitis B virus-related acute-on-chronic liver failure based on recommendations of the World Congress of Gastroenterology[J]. J Clin Hepatol,2018,34(3):548-552.(in Chinese)徐天娇,吕飒,游绍莉,等.基于世界胃肠病学大会提议的HBV相关慢加急性肝衰竭的临床特征及分型讨论[J].临床肝胆病杂志,2018,34(3):548-552.
    [12] ZHANG Q,HAN T,LI Y,et al. Predictors of progression into acute-on-chronic liver failure from acute deterioration of preexisting chronic liver disease[J]. Hepatol Res,2016,46(4):320-328.
    [13] MOREAU R,JALAN R,GINES P,et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology,2013,144(7):1426-1437,1437. e1-9.
    [14] MCKE MM,RUMYANTSEVA T,MCKE VT,et al. Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality[J]. Liver Int,2018,38(4):645-653.
    [15] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association. Diagnostic and treatment guidelines for liver failure(2012 version)[J]. Chin J Clin Infect Dis,2012,5(6):321-327.(in Chinese)中华医学会感染病学会分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华临床感染病杂志,2012,5(6):321-327.
    [16] PERDIGOTO DN,FIGUEIREDO P,TOML. The Role of the CLIF-C OF and the 2016 MELD in prognosis of cirrhosis with and without acute-on-chronic liver failure[J]. Ann Hepatol,2019,18(1):48-57.
    [17] SINHA VK,KO B. Hyponatremia in cirrhosis—pathogenesis,treatment,and prognostic significance[J]. Adv Chronic Kidney Dis,2015,22(5):361-367.
    [18] CARDENAS A,SOLA E,RODRIGUEZ E,et al. Hyponatremia influences the outcome of patients with acute-on-chronic liver failure:An analysis of the CANONIC study[J]. Crit Care,2014,18(6):700.
    [19] BAJAJ JS,TANDON P,O’LEARY JG,et al. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis[J]. Am J Gastroenterol,2018,113(9):1339.
    [20] AHLUWALIA V,HEUMAN DM,FELDMAN G,et al. Correction of hyponatraemia improves cognition,quality of life,and brain oedema in cirrhosis[J]. J Hepatol,2015,62(1):75-82.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1354) PDF downloads(114) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return